Ebos GroupASX:EBO -1.21%81 3-Year ROIIC % is 6.22 as of Jun. 2025, which is 14% below its 10-year median of 7.26. GuruFocus rates ASX:EBO with a GF Score™ of 81/100 and a GF Value™ of A$31.54 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 112 Medical Distribution companies, Ebos Group ranks better than 62.5% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Ebos Group's 3-Year ROIIC % for the quarter that ended in Jun. 2025 was 6.22%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Ebos Group's 3-Year ROIIC % or its related term are showing as below:
ASX:EBO's 3-Year ROIIC % is ranked better than 62.5% of 112
companies
in the Medical Distribution industry
Industry Median: 2.145
vs ASX:EBO: 6.22
Ebos Group (ASX:EBO) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Ebos Group 3-Year ROIIC % Related Terms
Ebos Group 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Ebos Group's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EBO vs MCK, CAH, COR: 3-Year ROIIC % Comparison
For the Medical Distribution subindustry, Ebos Group's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group 3-Year ROIIC % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Ebos Group's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Ebos Group (ASX:EBO) has a 3-Year ROIIC % of 6.22 as of Jun. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ebos Group and its competitors. This is 14% below median its historical median of 7.26. According to the industry distribution chart, Ebos Group ranks #42 out of 112 companies in the Medical Distribution industry, placing it in the top 37.5%.
Is Ebos Group's 3-Year ROIIC % too high?
Ebos Group's current 3-Year ROIIC % of 6.22 is 14% below median its 10-year median of 7.26. The Medical Distribution industry median 3-Year ROIIC % is 2.15. Ebos Group's value of 6.22 is 190% above this industry median. Based on the distribution chart, Ebos Group ranks #42 out of 112 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Ebos Group has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's 3-Year ROIIC % compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #42 out of 112 companies for 3-Year ROIIC %. This puts Ebos Group in the upper half of its industry. The industry median 3-Year ROIIC % is 2.15. Ebos Group's value of 6.22 is 190% above this benchmark. While the company's 10-year median is 7.26 vs. the industry median of 2.15, Ebos Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Medical Distribution company?
The median 3-Year ROIIC % among Medical Distribution companies is 2.15, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current 3-Year ROIIC % of 6.22 is 190% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median 3-Year ROIIC % is 2.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current 3-Year ROIIC % is 6.22, which is 14% below median its own 10-year median of 7.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.54, compared to a current price of A$17.98 — trading 43% below its estimated fair value. The current 3-Year ROIIC % is 6.22, which is 14% below median its 10-year median of 7.26 and 190% above the Medical Distribution industry median of 2.15. Ebos Group's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current 3-Year ROIIC % is 6.22 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$17.98 is trading 43% below its estimated GF Value™ of A$31.54.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
3-Year ROIIC %: 6.22 (14% below median its 10-year median of 7.26)
GF Value™: A$31.54 vs. price of A$17.98 (43% below fair value)
Industry Position: 190% above the Medical Distribution median (#42 of 112)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
81GF Score
Get the complete analysis for ASX:EBO
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
